Although anti-angiogenic strategies using VEGFR inhibitors, such as sorafenib and sunitinib, have shown considerable effects in ccRCC [3,4], most patients ultimately develop resistance [13,36]. The gene discussed is KDR; the disease is nonpapillary renal cell carcinoma.